Amneal and Zambon Receive Positive CHMP Opinion for Hopledo in Parkinson's Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: NASDAQ.COM
- Regulatory Progress: Amneal Pharmaceuticals and Zambon announced a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding Hopledo for treating Parkinson's disease and motor fluctuations, indicating a potential approval pathway in the European market.
- Market Demand Context: Over 80% of Parkinson's patients experience motor fluctuations during their disease progression, despite existing standard treatments of levodopa/carbidopa, highlighting the significant market need for Hopledo.
- Clinical Trial Support: The CHMP recommendation was backed by positive data from the Phase 3 RISE-PD trial, where patients treated with Hopledo showed a notable increase in Good ON time compared to those on immediate-release levodopa/carbidopa, demonstrating its efficacy advantage.
- Commercialization Plans: The licensing agreement signed in 2024 grants Zambon all commercialization rights in the UK, EU, and Switzerland, with Hopledo expected to be gradually introduced in European markets by October 2026, further expanding the company's market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMRX
Wall Street analysts forecast AMRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.920
Low
13.00
Averages
14.33
High
15.00
Current: 16.920
Low
13.00
Averages
14.33
High
15.00
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amneal and Zambon Receive Positive CHMP Opinion for Hopledo in Parkinson's Treatment
- Regulatory Progress: Amneal Pharmaceuticals and Zambon announced a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding Hopledo for treating Parkinson's disease and motor fluctuations, indicating a potential approval pathway in the European market.
- Market Demand Context: Over 80% of Parkinson's patients experience motor fluctuations during their disease progression, despite existing standard treatments of levodopa/carbidopa, highlighting the significant market need for Hopledo.
- Clinical Trial Support: The CHMP recommendation was backed by positive data from the Phase 3 RISE-PD trial, where patients treated with Hopledo showed a notable increase in Good ON time compared to those on immediate-release levodopa/carbidopa, demonstrating its efficacy advantage.
- Commercialization Plans: The licensing agreement signed in 2024 grants Zambon all commercialization rights in the UK, EU, and Switzerland, with Hopledo expected to be gradually introduced in European markets by October 2026, further expanding the company's market presence.
See More
EMA Recommends Approval of Hopledo for Parkinson's Disease
- EMA Recommendation: Amneal Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Hopledo for adults with Parkinson's disease experiencing moderate to severe motor fluctuations, indicating the drug's potential to enhance patient quality of life.
- Clinical Trial Results: The positive opinion is based on results from the Phase III RISE-PD trial, which demonstrated that Hopledo significantly increased Good ON time with fewer daily doses compared to immediate-release levodopa/carbidopa, highlighting its advantages in treatment efficacy and convenience.
- Market Rollout Plans: Zambon, the Italian chemical-pharmaceutical company holding commercialization rights for Hopledo in the EU, UK, and Switzerland, plans to begin rolling out the treatment across Europe in October 2026, pending final approval, which would provide new therapeutic options for patients.
- Current US Market Status: Hopledo is already approved and marketed in the United States as CREXONT for treating Parkinson's disease and Parkinson-like symptoms resulting from carbon monoxide or manganese poisoning, demonstrating its broad applicability across different markets.
See More
Hopledo® Receives Positive CHMP Opinion for Parkinson's Treatment
- Clinical Trial Results: Hopledo® demonstrated a significant increase in 'Good ON' time in the Phase 3 RISE-PD trial, requiring fewer daily doses compared to immediate-release levodopa/carbidopa, indicating its potential in Parkinson's disease treatment.
- Market Demand: With over one million people living with Parkinson's disease in the EU and more than 80% experiencing motor fluctuations, the introduction of Hopledo® will provide new treatment options, addressing the urgent need for innovative therapies.
- Strategic Partnership: Zambon has entered into an exclusive licensing agreement with Amneal Pharmaceuticals to commercialize Hopledo® in the EU, UK, and Switzerland, with a phased rollout expected to start in October 2026, showcasing the collaboration's potential in international markets.
- Drug Characteristics: Hopledo® features a unique formulation that combines immediate-release granules and extended-release pellets, offering rapid onset and prolonged therapeutic effects, aimed at extending the benefits of levodopa and significantly improving patients' quality of life.
See More
Estrogen Patch Shortage Impacts Hormone Therapy
- Surge in Demand: Prescriptions for estrogen patches have surged by 162% over the past two years, primarily due to the FDA's removal of a long-standing black box warning last fall, significantly impacting the supply-demand balance in the market.
- Production Challenges: Three types of estrogen patches are currently in shortage; while the FDA has not officially declared a shortage, manufacturers like Amneal are working to ramp up production to meet rising demand, highlighting the complexities and challenges in the manufacturing process.
- Exploration of Alternatives: With patches in short supply, doctors are recommending estrogen gels or customized creams from compounding pharmacies, although these alternatives are often not covered by insurance, placing an additional financial burden on patients.
- Uncertain Market Outlook: Experts predict that it may take one to two years for manufacturers to balance supply and demand, meaning women may face difficulties in treatment options during this period, adversely affecting their quality of life and health management.
See More
Amneal Pharmaceuticals Advances Drug Development with Positive ELEVATE-PD Results
- ELEVATE-PD Trial Results: Amneal Pharmaceuticals reported positive interim Phase 4 results from the ELEVATE-PD trial, indicating that CREXONT extended-release carbidopa/levodopa capsules significantly improved 'Good On' time, reduced 'Off' time, and enhanced motor scores in Parkinson's patients across various prior treatment regimens, thereby reinforcing its market position.
- FDA Approval of New Drug: Amneal secured FDA approval for a ready-to-use romidepsin injection, along with 180 days of Competitive Generic Therapy exclusivity, marking the return of this important oncology treatment to the U.S. market and highlighting the company's strategic shift towards higher-value complex products.
- Investment Narrative Shift: With the advancements in CREXONT's continuous 'Good On' intervals, Amneal's investment narrative is transitioning towards a more diversified portfolio of higher-value specialty, biosimilar, and complex products, although the company still faces significant generic price pressures and high leverage risks that could impact future growth.
- Financial Outlook: Amneal projects revenues of $3.7 billion and earnings of $325.7 million by 2029, with fair value estimates ranging from $11.94 to $82.75, reflecting divergent investor perspectives on the company's future performance and underscoring the need for a multifaceted approach in decision-making.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Amneal and Zambon Receive Positive CHMP Opinion for Hopledo in Parkinson's Treatment
- Regulatory Progress: Amneal Pharmaceuticals and Zambon announced a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding Hopledo for treating Parkinson's disease and motor fluctuations, indicating a potential approval pathway in the European market.
- Market Demand Context: Over 80% of Parkinson's patients experience motor fluctuations during their disease progression, despite existing standard treatments of levodopa/carbidopa, highlighting the significant market need for Hopledo.
- Clinical Trial Support: The CHMP recommendation was backed by positive data from the Phase 3 RISE-PD trial, where patients treated with Hopledo showed a notable increase in Good ON time compared to those on immediate-release levodopa/carbidopa, demonstrating its efficacy advantage.
- Commercialization Plans: The licensing agreement signed in 2024 grants Zambon all commercialization rights in the UK, EU, and Switzerland, with Hopledo expected to be gradually introduced in European markets by October 2026, further expanding the company's market presence.
See More
EMA Recommends Approval of Hopledo for Parkinson's Disease
- EMA Recommendation: Amneal Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Hopledo for adults with Parkinson's disease experiencing moderate to severe motor fluctuations, indicating the drug's potential to enhance patient quality of life.
- Clinical Trial Results: The positive opinion is based on results from the Phase III RISE-PD trial, which demonstrated that Hopledo significantly increased Good ON time with fewer daily doses compared to immediate-release levodopa/carbidopa, highlighting its advantages in treatment efficacy and convenience.
- Market Rollout Plans: Zambon, the Italian chemical-pharmaceutical company holding commercialization rights for Hopledo in the EU, UK, and Switzerland, plans to begin rolling out the treatment across Europe in October 2026, pending final approval, which would provide new therapeutic options for patients.
- Current US Market Status: Hopledo is already approved and marketed in the United States as CREXONT for treating Parkinson's disease and Parkinson-like symptoms resulting from carbon monoxide or manganese poisoning, demonstrating its broad applicability across different markets.
See More
Hopledo® Receives Positive CHMP Opinion for Parkinson's Treatment
- Clinical Trial Results: Hopledo® demonstrated a significant increase in 'Good ON' time in the Phase 3 RISE-PD trial, requiring fewer daily doses compared to immediate-release levodopa/carbidopa, indicating its potential in Parkinson's disease treatment.
- Market Demand: With over one million people living with Parkinson's disease in the EU and more than 80% experiencing motor fluctuations, the introduction of Hopledo® will provide new treatment options, addressing the urgent need for innovative therapies.
- Strategic Partnership: Zambon has entered into an exclusive licensing agreement with Amneal Pharmaceuticals to commercialize Hopledo® in the EU, UK, and Switzerland, with a phased rollout expected to start in October 2026, showcasing the collaboration's potential in international markets.
- Drug Characteristics: Hopledo® features a unique formulation that combines immediate-release granules and extended-release pellets, offering rapid onset and prolonged therapeutic effects, aimed at extending the benefits of levodopa and significantly improving patients' quality of life.
See More
Estrogen Patch Shortage Impacts Hormone Therapy
- Surge in Demand: Prescriptions for estrogen patches have surged by 162% over the past two years, primarily due to the FDA's removal of a long-standing black box warning last fall, significantly impacting the supply-demand balance in the market.
- Production Challenges: Three types of estrogen patches are currently in shortage; while the FDA has not officially declared a shortage, manufacturers like Amneal are working to ramp up production to meet rising demand, highlighting the complexities and challenges in the manufacturing process.
- Exploration of Alternatives: With patches in short supply, doctors are recommending estrogen gels or customized creams from compounding pharmacies, although these alternatives are often not covered by insurance, placing an additional financial burden on patients.
- Uncertain Market Outlook: Experts predict that it may take one to two years for manufacturers to balance supply and demand, meaning women may face difficulties in treatment options during this period, adversely affecting their quality of life and health management.
See More
Amneal Pharmaceuticals Advances Drug Development with Positive ELEVATE-PD Results
- ELEVATE-PD Trial Results: Amneal Pharmaceuticals reported positive interim Phase 4 results from the ELEVATE-PD trial, indicating that CREXONT extended-release carbidopa/levodopa capsules significantly improved 'Good On' time, reduced 'Off' time, and enhanced motor scores in Parkinson's patients across various prior treatment regimens, thereby reinforcing its market position.
- FDA Approval of New Drug: Amneal secured FDA approval for a ready-to-use romidepsin injection, along with 180 days of Competitive Generic Therapy exclusivity, marking the return of this important oncology treatment to the U.S. market and highlighting the company's strategic shift towards higher-value complex products.
- Investment Narrative Shift: With the advancements in CREXONT's continuous 'Good On' intervals, Amneal's investment narrative is transitioning towards a more diversified portfolio of higher-value specialty, biosimilar, and complex products, although the company still faces significant generic price pressures and high leverage risks that could impact future growth.
- Financial Outlook: Amneal projects revenues of $3.7 billion and earnings of $325.7 million by 2029, with fair value estimates ranging from $11.94 to $82.75, reflecting divergent investor perspectives on the company's future performance and underscoring the need for a multifaceted approach in decision-making.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
